Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Robert I. BlumPresident & CEO | CytokineticsCYTK | Open-market sale10b5-1 plan | 09/28 | 09/28 | 7,500 sh | $65.46 | $490,950 | −2.6% |
CytokineticsCYTK | Open-market sale10b5-1 plan | 06/24–06/29 | 06/29 | 41,864 sh2 trades | $82.50avg. | $3,453,869 | −39.8% | |
Fady Ibraham MalikEVP Research & Development | CytokineticsCYTK | Open-market sale10b5-1 plan | 06/23 | 06/23 | 3,500 sh | $79.51 | $278,285 | −2.2% |
Robert I. BlumPresident & CEO | CytokineticsCYTK | Open-market sale10b5-1 plan | 06/15 | 06/15 | 7,500 sh | $70.46 | $528,450 | −1.9% |
Fady Ibraham MalikEVP Research & Development | CytokineticsCYTK | Open-market sale10b5-1 plan | 06/09 | 06/09 | 3,500 sh | $67.98 | $237,930 | −2.2% |
B. Lynne ParshallDirector | CytokineticsCYTK | Open-market sale10b5-1 plan | 06/01 | 06/01 | 5,000 sh | $74.08 | $370,400 | −24.1% |
Edward M. Md KayeDirector | CytokineticsCYTK | Open-market sale10b5-1 plan | 06/01 | 06/01 | 2,933 sh | $76.09 | $223,171.97 | −22.2% |
Andrew CallosEVP, Chief Commercial Officer | CytokineticsCYTK | Open-market sale10b5-1 plan | 06/01 | 06/01 | 15,000 sh | $74.08 | $1,111,200 | −20.4% |
Robert I. BlumPresident & CEO | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/27 | 05/28 | 7,500 sh | $77.21 | $579,075 | −1.9% |
Fady Ibraham MalikEVP Research & Development | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/19 | 05/20 | 3,500 sh | $75.69 | $264,915 | −2.2% |
Robert I. BlumPresident & CEO | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/14 | 05/14 | 7,500 sh | $77.92 | $584,400 | −1.8% |
John T. HendersonDirector | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/05 | 05/05 | 20,000 sh | $75.97 | $1,519,400 | −21.0% |
Wendell WierengaDirector | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/05 | 05/05 | 4,032 sh | $75.00 | $302,400 | −11.0% |
Fady Ibraham MalikEVP Research & Development | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/05 | 05/05 | 3,500 sh | $77.37 | $270,795 | −2.2% |
Sung LeeEVP, CFO | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/05 | 05/05 | 23,906 sh | $76.87 | $1,837,654.22 | −27.4% |
Andrew CallosEVP, Chief Commercial Officer | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/05 | 05/05 | 11,333 sh | $77.25 | $875,474.25 | −16.2% |
Andrew CallosEVP, Chief Commercial Officer | CytokineticsCYTK | Open-market sale10b5-1 plan | 05/01 | 05/04 | 15,857 sh | $65.00 | $1,030,705 | −21.3% |
Andrew CallosEVP, Chief Commercial Officer | CytokineticsCYTK | Open-market sale10b5-1 plan | 04/30 | 04/30 | 15,000 sh | $63.26 | $948,900 | −20.4% |
Robert I. BlumPresident & CEO | CytokineticsCYTK | Open-market sale10b5-1 plan | 04/29 | 04/29 | 7,500 sh | $59.62 | $447,150 | −1.8% |
Fady Ibraham MalikEVP Research & Development | CytokineticsCYTK | Open-market sale10b5-1 plan | 04/21 | 04/21 | 3,500 sh | $65.69 | $229,915 | −2.2% |
